Imara

Imara Inc. is a biotechnology company that is carving a niche in pioneering therapeutic advancements with innovative solutions for rare genetic hemoglobin disorders. Established in 2015, Imara is driven by its slogan, "Pioneering therapeutic advancements with innovative solutions for rare genetic hemoglobin disorders." The company is focused on creating groundbreaking treatments for rare genetic disorders related to hemoglobin. Imara's flagship product, IMR-687, is a highly selective and potent small molecule inhibitor of PDE9. This oral, once-daily treatment aims to modify the course of sickle cell disease and beta-thalassemia by targeting red blood cells, white blood cells, adhesion mediators, and other cell types through its multimodal mechanism of action. Notably, Imara has recently received a $50.00M Post-IPO Equity investment on 14 July 2021, signifying a promising development in its journey. With its focus on Biopharma, Biotechnology, and Health Care industries, Imara is poised to make a significant impact in the field of rare genetic disorders.